Acrivon Therapeutics, Inc. (ACRV) Live Share Price, Invest From India

Acrivon Therapeutics, Inc. Stock Performance

as on October 24, 2026 at 2:15 pm IST

Day's Low
Day's High
$1.68
Day's Price Range
$1.82
$1.73
2.89%
Downside
5.20%
Upside
52 Week's Low
52 Week's High
$1.27
52-Week Price Range
$3.56
$1.73
26.59%
Downside
105.78%
Upside

Acrivon Therapeutics, Inc. share price movements today

Previous Close: $1.76
Open: $1.82
Volume: 447.2K
Market Cap: $74.1M
Day's Low - High: $1.68 - $1.82
52 Week Low - High: $1.27 - $3.56

Acrivon Therapeutics, Inc. Historical Returns

1 Month Return: -18.4 %
3 Month Return: + 8.12 %
1 Year Return: -16.43 %
3 Year Return: -68.08 %
5 Year Return: 0 %

Acrivon Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Acrivon Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$74.1M

EPS (TTM)

-1.88

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.94

Industry PE ratio

-3.17

PEG Ratio

-0.05

EBITDA

-78.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-70.14%

Acrivon Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Acrivon Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Acrivon Therapeutics, Inc.	Buy	$74.1M	NA	-0.94	0.00%	0.00%
Moderna	Neutral	$80.9B	-38.72%	-25.39	-12.57%	0.00%
BeOne Medicines	StrongBuy	$43.5B	NA	26.46	87.82%	0.00%
Vertex Pharmaceuticals	StrongBuy	$135.6B	185.49%	30.90	86.04%	0.00%
Regeneron	Buy	$83.1B	40.65%	19.56	84.86%	0.46%

Stock Returns calculator for Acrivon Therapeutics, Inc. Stock including INR - Dollar returns

The Acrivon Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Acrivon Therapeutics, Inc. investment value today

Current value as on today

₹90,334

Returns

-₹9,666

(-9.67%)

Returns from Acrivon Therapeutics, Inc. Stock

-₹16,425 (-16.43%)

Dollar Impact

₹6,759 (+6.76%)

Analyst Recommendation on Acrivon Therapeutics, Inc. Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Acrivon Therapeutics, Inc.. Average target price of $11.5

Acrivon Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Acrivon Therapeutics, Inc..

What analysts predicted

84.96%UPSIDE

Target Price

$11.5

Current Price

$1.73

Analyzed by

2 Analysts

High

Target

$11.50

Low

Acrivon Therapeutics, Inc. target price $11.5, a slight upside of 84.96% compared to current price of $1.73. According to 2 analysts rating.

Indian Investors' Interest in Acrivon Therapeutics, Inc. Stock

Search interest for Acrivon Therapeutics, Inc. Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 24, 2026 to October 24, 2026

Change:5% versus previous 30 day period

Acrivon Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	0	0	0	-	0	0	-
Operating Income	-17	-21	-25	-24	-21	-22	-19	-20	-19	-18
EBITDA	-16	-18	-22	-22	-19	-20	-17	-24	-18	-17
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	0	-	-	0	-1	-1
Operating Income	-3	-16	-32	-67	-89	-84
EBITDA	-5	-16	-30	-59	-79	-76
Interest Expense	-	-	-	-	-	-
Depreciation	0	0	0	0	1	1
Income Before Tax	-5	-16	-31	-60	-80	-77
Income Tax Expense	-	-	-	-	-	-
Net Income	-5	-16	-31	-60	-80	-77
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Operating Cash Flow	-17	-13	-17	-17	-19	-16	-12	-15	-20	-14
Investing Cash Flow	5	-88	16	14	19	19	5	21	13	14
Financing Cash Flow	0	123	-1	0	0	0	0	0	0	7
Change in Cash	-11	21	-2	-3	0	2	-6	6	-7	7

Acrivon Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-5	-16	-31	-60	-80	-77
Operating Cash Flow	-2	-13	-30	-42	-65	-63
Investing Cash Flow	0	0	-141	50	-51	66
Financing Cash Flow	2	112	101	-1	121	0
Change in Cash	0	98	-70	6	3	1

Global Institutional Holdings in Acrivon Therapeutics, Inc.

Check out the Institutions with significant holdings in Acrivon Therapeutics, Inc..

Funds	Holdings
Peter Kolchinsky	28.54%
Vanguard	2.54%
VANGUARD INDEX FUNDS	1.68%
Fidelity Concord Street Trust	0.42%
Bridgeway Funds, Inc.	0.36%

See all

Insights on Acrivon Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, ACRV stock has moved up by 5.5%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 648.3% return, outperforming this stock by 664.7%
NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 150.9% return, outperforming this stock by 219.0%

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Organisation	Acrivon Therapeutics, Inc.
Headquarters	480 Arsenal Way, Watertown, MA, 02472, US
Industry	Biotechnology
CEO	Peter Blume-Jensen

Key Management of Acrivon Therapeutics, Inc.

Name	Title
Ms. Katharine Peterson CPA	Vice President of Finance & Accounting
Mr. Bruce Close	Vice President of Quality & Compliance
Ms. Mary-Alice Miller J.D.	Chief Legal Officer & Corporate Secretary
Dr. Erick Gamelin M.D., Ph.D.	Chief Development Officer
Dr. Jesper V. Olsen Ph.D.	Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Mr. Joon Jung Ph.D.	VP & Head of Data Science
Dr. Peter Blume-Jensen M.D., Ph.D.	Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Ms. Kristina Masson M.B.A., Ph.D.	Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
Dr. Eric J. Devroe Ph.D.	Chief Operating Officer
Dr. Adam D. Levy M.B.A., Ph.D.	CFO & Principal Financial Officer

FAQs

What is Acrivon Therapeutics, Inc. share price today?

Acrivon Therapeutics, Inc. share price today is $1.73 as on October 24, 2026 at 8:45 am IST at the close of the market. Acrivon Therapeutics, Inc. share today touched a day high of $1.82 and a low of $1.68.

What is the 52 week high and 52 week low for Acrivon Therapeutics, Inc. share?

Acrivon Therapeutics, Inc. share touched a 52 week high of $3.56 on January 7, 2026 and a 52 week low of $1.27 on March 30, 2026. Acrivon Therapeutics, Inc. stock price today i.e. October 24, 2026 at 8:45 am IST is closed at $1.73,which is 51.40% down from its 52 week high and 36.22% up from its 52 week low.

What is Acrivon Therapeutics, Inc.'s market capitalisation today?

Acrivon Therapeutics, Inc. market capitalisation is $0.00T as on October 24, 2026 at 8:45 am IST.

How to invest in Acrivon Therapeutics, Inc. Stock (ACRV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Acrivon Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Acrivon Therapeutics, Inc. Stock (ACRV) from India?

Indian investors can start investing in Acrivon Therapeutics, Inc. (ACRV) shares with as little as ₹94.94000244140625 or $1 (as of October 24, 2026 at 6:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Acrivon Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on October 24, 2026 at 6:42 pm IST). Based on Acrivon Therapeutics, Inc. share’s latest price of $1.73 as on October 24, 2026 at 8:45 am IST, you will get 5.7803 shares of Acrivon Therapeutics, Inc.. Learn more about fractional shares .